false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
AAV Gene Therapy for IgA Nephropathy
AAV Gene Therapy for IgA Nephropathy
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Mohamed Salim described the development of podocyte-targeted AAV gene therapy, from laboratory proof of concept to clinical testing. Podocytes are attractive targets because they are central to many glomerular diseases, are long-lived cells, and can be targeted using cell-specific promoters.<br /><br />In mouse models of genetic podocin deficiency, AAV delivery restored podocin function, reduced proteinuria, improved kidney pathology, and extended survival. Direct kidney delivery in pigs achieved strong podocyte expression at much lower doses than systemic administration, with limited off-target expression—an important advantage for safety and manufacturing.<br /><br />The team also used podocyte-targeted delivery of complement factor I (CFI) in a mouse model of IgA nephropathy. Treatment reduced complement deposition, proteinuria, and kidney damage, supporting the approach for non-genetic diseases.<br /><br />A phase 1/2 trial of the IgA nephropathy therapy is now recruiting adults in the UK and US. It will assess safety and dosing, with proteinuria and complement measures among the secondary outcomes. Salim described this as the first renal AAV gene therapy administered to people. An Alport syndrome program is also advancing, while development for podocin-related disease remains a funding priority.
Asset Caption
Moin A. Saleem, MD, MBBS, MBChB, PhD
Meta Tag
Speaker
Moin Saleem
Keywords
podocyte-targeted AAV gene therapy
podocin deficiency
IgA nephropathy
complement factor I
proteinuria
Alport syndrome
kidney gene therapy
Moin Saleem
×
Please select your language
1
English